HER2 as a Therapeutic Target in Ovarian Cancer
نویسندگان
چکیده
Members of the human epidermal growth factor receptor (HER) family—epidermal growth factor receptor (EGFR, HER1), HER2, HER3, and HER4—are transmembrane tyrosine kinase receptors that are important mediators of cell growth, development, and survival. Activation of the HER tyrosine kinases triggers intracellular signaling pathways, including the MAPK and PI3K-Akt pathways (Olayioye et al., 2000) (Figure 1).
منابع مشابه
Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling
The activation status of a set of pro-oncogenic tyrosine kinases in ovarian cancer patient samples was analyzed to define potential therapeutic targets. Frequent activation of HER family receptor tyrosine kinases, especially HER2, was observed. Studies in ovarian cancer cell lines confirmed the activation of HER2. Moreover, knockdown of HER2 caused a strong inhibition of their proliferation. An...
متن کاملBelgian guidelines for HER2 testing in gastric cancer
1 4 Introduction Human epidermal growth factor receptor 2 (HER2, ErbB2, Neu) is a 185-kDa transmembrane tyrosine kinase receptor. It is a member of the EGFR family and plays a central role in growth factor signal transduction. HER2 overexpression/amplification is implicated in the development of various solid tumours and plays a pivotal role in oncogenic transformation and tumorogenesis.1 The H...
متن کاملEGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells
Background: Epithelial ovarian cancer (EOC) is one of the most lethal gynecological malignancy worldwide. Although the majority of EOC patients achieve clinical remission after induction therapy, over 80% relapse and succumb to the chemoresistant disease. Previous investigations have demonstrated the association of epidermal growth factor receptor (EGFR) with resistance to cytotoxic chemotherap...
متن کاملHER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.
HER2 overexpression in breast cancer confers increased tumor aggressiveness. Although anti-HER2 therapies have improved patient outcome, resistance ultimately occurs. PARP inhibitors target homologous recombination (HR)-deficient tumors, such as the BRCA-associated breast and ovarian cancers. In this study, we show that HER2+ breast cancers are susceptible to PARP inhibition independent of an H...
متن کاملبررسی رابطه پروتوانکوژن HER2 با فاکتورهای پروگنوستیک سرطان پستان
Background: Breast cancer is the most common female malignancy world wide and in Iran as well and is the second cause of death due to malignancy after lung cancer. Varieties of factors such as estrogen and progesterone receptors, and axillary lymph node involvement may influence the prognosis and therapeutic approach. However, mutation in HER2 gene may also affect the prognosis. In this study...
متن کامل